Gene test could guide leukemia treatment after chemo

NCT ID NCT02756962

Ongoing Knowledge-focused Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether checking for leftover leukemia-related gene mutations after initial chemotherapy can help predict relapse and survival in adults with acute myeloid leukemia (AML). Researchers will follow 107 patients aged 18-60 who are in remission after chemo. Those whose mutations have cleared will receive standard consolidation chemo, while those with persistent mutations may get a stem cell transplant. The goal is to see if this genetic approach improves survival compared to historical averages.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cytarabine (chemotherapy) and allogeneic stem cell transplant
What this could lead to: If successful, this could help doctors better predict which AML patients need more aggressive treatment after initial chemotherapy, potentially improving survival rates.
What could go wrong: This is a Phase 2 study with only 107 participants, so results may not apply to all patients. The approach relies on genetic testing that may not capture all mutations, and the benefit of changing treatment based on results is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

University of Florida

Gainesville, Florida, 32608, United States
University of Rochester

Rochester, New York, 14642, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.